CDK4 and sarcoma: The phosphorylation of CDK4 at T172 is indicative of its activity and sensitivity to CDK4/6 inhibitors. The amplification of CDK4 is associated with resistance to CDK4/6 inhibitors in sarcoma and glioblastoma